NDM-1 Gene (New Delhi Metallo-β-lactamase-1)
The NDM-1 gene (New Delhi Metallo-β-lactamase-1) is associated with one of today’s most concerning bacterial resistance mechanisms: the production of metallo-β-lactamases capable of inactivating carbapenem antibiotics. These antimicrobials are often used as a last-line therapy for severe infections caused by multidrug-resistant bacteria.
The spread of the NDM-1 gene poses a significant public health challenge, especially in hospital settings, where rapid identification is essential for outbreak control and appropriate clinical management.
The NDM-1 gene encodes a zinc-dependent metallo-β-lactamase enzyme capable of hydrolyzing virtually all β-lactam antibiotics, including:
Penicillins
Cephalosporins
Carbapenems
The gene is generally located on plasmids, which facilitates horizontal transfer between different bacterial species, such as:
Klebsiella pneumoniae
Escherichia coli
Acinetobacter baumannii
Pseudomonas aeruginosa
This genetic mobility contributes to rapid intra- and inter-hospital spread.
Since its first identification, NDM-1 has been detected in multiple countries, with global spread. Transmission occurs mainly in hospital settings, but it may also be present in the community.
Risk factors include:
Prolonged hospital stays
Prior use of broad-spectrum antibiotics
Invasive procedures
International transfer of patients
Molecular surveillance has become an essential component in containing this resistance mechanism.
Infections caused by NDM-1–producing bacteria are associated with:
High morbidity and mortality rates
Extremely limited treatment options
Need for alternative antibiotics that may be more toxic
Longer hospital stays
These infections may include:
Sepsis
Hospital-acquired pneumonia
Complicated urinary tract infections
Intra-abdominal infections
Rapid identification of the gene is crucial for the immediate adoption of clinical and epidemiological measures.
Phenotypic methods may suggest carbapenem resistance, but they do not specifically identify the genetic mechanism involved.
Real-Time PCR enables:
Specific detection of the NDM-1 gene
High sensitivity and specificity
Rapid results
Use across different types of clinical samples
Molecular confirmation is essential to differentiate resistance mechanisms and guide appropriate interventions.
Controlling the spread of NDM-1 requires:
Active screening of at-risk patients
Isolation of positive cases
Strict biosafety protocols
Antimicrobial stewardship programs
Ongoing epidemiological monitoring
Early detection is one of the pillars of these strategies.
The presence of the NDM-1 gene is considered a critical priority by global health authorities. Its impact includes:
Significant increase in hospital costs
Therapeutic limitation
Risk of hospital outbreaks
Potential community spread
Implementing rapid molecular tools is essential to mitigate these risks.
The Bioperfectus Real-Time PCR Kit for Detection of the NDM-1 Gene was developed to quickly, sensitively, and specifically identify the presence of the gene responsible for producing the NDM-1 metallo-β-lactamase.
Direct molecular detection of the NDM-1 gene
High diagnostic sensitivity and specificity
Rapid results, reducing time to clinical decision-making
Support for the immediate implementation of infection control measures
Support for hospital epidemiological surveillance
By incorporating the Bioperfectus Kit into laboratory routine, healthcare institutions strengthen their strategies for diagnosing and controlling antimicrobial resistance, promoting greater patient safety and improved management of infectious risks.
Real-Time PCR technology not only identifies the presence of resistance, but also strategically contributes to containing one of today’s most critical bacterial mechanisms.
